Hepatitis B Immune Globulin Clinical Trials For HBV Prevention In Liver Transplant Patients To Be Discussed By Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Nabi Pharmaceuticals expects FDA action on Nabi-HB immune globulin BLA by mid-2004. Committee will also discuss supplemental testing for HIV and HCV, and platelet apheresis quality control.